An Open-label, Single-arm, Multi-center Study to Evaluate the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Participants With Refractory Generalized Myasthenia Gravis (gMG)
Latest Information Update: 22 Jan 2025
Price :
$35 *
At a glance
- Drugs Eculizumab (Primary)
- Indications Myasthenia gravis
- Focus Therapeutic Use
- Sponsors Alexion AstraZeneca Rare Disease
- 16 Jan 2025 Planned End Date changed from 15 Dec 2026 to 21 Dec 2026.
- 16 Jan 2025 Planned primary completion date changed from 15 Dec 2026 to 21 Dec 2026.
- 16 Jan 2025 Status changed from not yet recruiting to recruiting.